Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v5.i2-3.100
pages 313-329

The c-erbB-2 Protein in Oncogenesis: Molecular Structure to Molecular Epidemiology

Paul W. Brandt-Rauf
Division of Environmental Sciences, Department of Medicine and Comprehensive Cancer Center, Columbia University, 60 Haven Avenue, New York, N.Y. 10032
Matthew R. Pincus
Department of Pathology, SUNY Health Sciences Center, 750 East Adams Street, Syracuse, N.Y. 13210
Walter P. Carney
Oncogene Sciences/ Applied Biotechnology, 80 Rogers Street, Cambridge, MA 01242


The c-erbB-2 (HER-2, neu) oncogene has been implicated frequently in many human tumors. This oncogene codes for a 185-kDa protein that functions as a transmembrane growth factor receptor. Overexpression of the normal protein or point mutations in the transmembrane domain of the protein have been shown to have a transforming effect. Molecular structure studies of the transmembrane domain provide a plausible explanation for this transforming effect in both cases and relate this to the process of receptor dimerization in the membrane, degradation of the protein with release of the extracellular domain (ECD) into the extracellular environment, and aberrant signal transduction. The release of the ECD into the extracellular environment provides a potential biomarker for the study of signal transduction at the molecular level in vivo. The ECD can be quantitated immunologically in the serum of individuals with cancers associated with p185 overexpression and in individuals at risk for the development of such cancers and can be used to distinguish these individuals from normal, healthy controls. Identification of such individuals by their serum ECD levels combined with specific chemotherapeutic/ chemoprophylactic interventions could allow for improvement treatment and prevention of c-erbB-2-related cancers.

Articles with similar content:

Glucose Transporter Regulation in Cancer: A Profile and the Loops
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 3
Zhenyu Zhang, Mutong Zhao
Tissue-Specific Transformation by Oncogenic Mutants of Epidermal Growth Factor Receptor
Critical Reviews™ in Oncogenesis, Vol.5, 1994, issue 4
H. J. Kung, T. H. Carter
Emerging Roles of MicroRNAs in the Wnt Signaling Network
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Troels Schepeler
Targeting the Regulatory Machinery of BIM for Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Steven Grant, Hisashi Harada
Genes Associated with Human Cancers: Their Expressions, Features, Functions, and Significance
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 3
Ravi Maddaly, Bellona Sahu, Divya K. Mohan